[Current views on the interaction between the treatment of osteoporosis and cardiovascular diseases]
Tomasz Zapolski1, Andrzej Wysokiński2
1Katedra i Klinika Kardiologii, Uniwersytet Medyczny, Lublin,
Insights
Menopause increases risks for osteoporosis and cardiovascular disease. This study explores their potential link and how treatments for one condition may affect the other, impacting drug choices.
Area of Science:
- Gerontology
- Cardiology
- Endocrinology
Background:
- Osteoporosis and atherosclerotic disease are common post-menopause, often viewed as independent age-related conditions.
- Emerging evidence suggests a potential link between cardiovascular disease and osteoporosis.
- Understanding this connection is crucial for managing patient health effectively.
Purpose of the Study:
- To investigate the association between cardiovascular disease and osteoporosis.
- To analyze the mutual beneficial and adverse effects of drugs used for these conditions.
- To evaluate drug interactions between osteoporosis treatments and cardiovascular medications.
Main Methods:
- Review of current literature on drug interactions between cardiovascular and osteoporosis therapies.
- Analysis of side effects of cardiological drugs on bone health.
- Evaluation of potential benefits of cardiovascular drugs for osteoporosis prevention.
- Examination of adverse cardiovascular effects of osteoporosis drugs.
- Review of bisphosphonates, strontium ranelate, hormone replacement therapy (HRT), and selective estrogen receptor modulators (SERMs).
- Discussion of cardiac effects of calcium and related metabolic drugs (vitamin D, parathormone, calcitonin).
Main Results:
- Osteoporosis treatments can have adverse effects on the cardiovascular system.
- Cardiovascular drugs may impact bone health, both positively and negatively.
- Specific drug classes like bisphosphonates and SERMs require careful consideration regarding cardiovascular and bone health.
- Calcium and vitamin D supplementation require monitoring for cardiac effects.
Conclusions:
- The interplay between osteoporosis and cardiovascular disease necessitates a comprehensive approach to treatment.
- Clinicians must consider potential drug interactions and side effects when managing patients with both conditions.
- Further research is needed to optimize therapeutic strategies for post-menopausal women at risk for both osteoporosis and cardiovascular disease.
Abstract:
The most common medical conditions after menopause are osteoporosis and atherosclerotic disease. Traditionally these two conditions were considered unrelated and their coexistence has been attributed to independent processess exclusively reated to age. The possible link between cardiovascular disease and osteoporosis stimulates today to analyse not only the evidence of a possible association, but also to identify mutual beneficial and adverse effects of drugs used in these two diseases. That's why, the focus on the interference between osteoporosis treatment and drugs used for atherosclerosis is made. Moreover side effects of cardiological drug considering bones are analysed. Additionally possible advantages of selected drugs used for cardiovascular diseases on osteoporosis prevention are evaluated. Drugs used for osteoporosis treatment may heave adverse effects on cardiovascular system. The article has detailed analyses of current drug classes, such as the bisphosphonates, strontium ranelate as well as a review of the controversy surrounding hormone replacement therapy (HRT) and the selective oestrogen receptor modulators (SERMs). Lastly discussion of adverse effects on the heart of calcium and drugs influencing calcium metabolism such as vitamin D, parathormone and calcitonin is performed.
Related Concept Videos
01:40Bone Remodeling
01:20Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:31Osteoclasts in Bone Remodeling